Important Investor Alert: Class Action Lawsuit Filed Against ADMA Biologics, Inc.

Pomerantz LLP, a well-respected law firm, has officially announced the filing of a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). This legal action is particularly significant for investors who have experienced losses in their investments with the company. The firm urges concerned individuals to reach out as soon as possible to discuss their options and potential legal steps.

Background on ADMA Biologics

ADMA Biologics is a leading biopharmaceutical company that specializes in the development and manufacturing of human immunoglobulin products. Their offerings are primarily aimed at treating certain immunodeficiencies. As with many companies in the biopharmaceutical sector, ADMA has faced scrutiny over its business practices. There are allegations suggesting that the company may have engaged in securities fraud, which has raised serious concerns for investors regarding transparency and ethical conduct.

The Allegations

The crux of the lawsuit revolves around claims of deceptive practices by ADMA and its officers or directors. Under scrutiny is whether the company's actions have compromised the integrity of their reported financial health.

On March 24, 2026, Culper Research published a report that suggested the company’s growth was artificially inflated through questionable methods, including alleged channel stuffing. This report asserted that genuine revenue figures were significantly lower than what had been publicly reported. The report claimed that ADMA's revenue actually fell by about 3% in 2025 when adjusted for these dubious practices, contradicting the publicly stated growth rate of over 20%.

Following this adverse report, there was a notable impact on ADMA's stock price, which plummeted by approximately $2.26 per share, marking a 16.63% drop. Just days later, Cantor Fitzgerald followed up with a downgrade of ADMA’s stock rating, reinforcing market concerns over the company’s lack of a robust response to the allegations.

Key Dates and Actions for Investors

Investors who purchased ADMA securities during the class period are strongly encouraged to consider their legal options. Significant upcoming deadlines are looming, with the date of August 10, 2026, marking the last opportunity for investors to apply for the role of Lead Plaintiff within the class action suit. Interested parties may obtain a copy of the complaint and gather more detailed information about joining the class action by visiting Pomerantz Law's website.

It is essential that affected investors act quickly, as participating in the class action can provide a crucial avenue for recovering losses incurred due to alleged misconduct by ADMA Biologics.

About Pomerantz LLP

Pomerantz is recognized as a premier law firm in the field of corporate litigation, securities, and antitrust class actions. With a long-standing tradition dating back more than 85 years, they have consistently fought for the rights of victims of corporate wrongdoing. Their reputation precedes them, having secured numerous notable settlements for clients affected by securities fraud and other corporate malpractices.

For investors wishing to take advantage of this opportunity for legal recourse, reaching out to Danielle Peyton at Pomerantz is a practical first step. They can be contacted via email or at their office number, which is listed in the announcement. Investing in legal support can potentially mitigate losses and uphold investor rights in the face of corporate misdeeds.